STREAMLINING HEALTHCARE BLOG

Posts Tagged government advocacy

USTR Releases List Of Chinese Imports Subject To Tariffs

USTR Releases List Of Chinese Imports Subject To Tariffs

On June 15, the United States Trade Representative (USTR) identified $50 billion in Chinese imports that will be subject to a 25% tariff. The agency has published two lists of products affected by the tariff. The first contains $34 billion worth of Chinese goods and will take effect July 6, 2018. The second covers $16 [...]

Continue Reading →

Posted in: Advocacy and Gov Affairs, HIDA News, Policy Outlook & Analysis, Research & Analysis

Leave a Comment (0) →

In Trump’s First Year, CMS Pursues Medicare Deregulation

In its first year, the Trump Administration has made a number of key changes at the Centers for Medicare and Medicaid Services (CMS) that aim to reduce the regulatory burden on providers. Three examples of these moves include: CMS has cancelled the mandatory hip fracture and bundled payment models. The agency has also reduced the [...]

Continue Reading →

Posted in: Advocacy and Gov Affairs, HIDA Resources, Medicaid/Medicaid

Leave a Comment (0) →

Is Your Pedigree Showing?

Is Your Pedigree Showing?

Over half the states in the U.S. have laws related to the tracing, or pedigree, of the pharmaceutical drug supply chain.  Many of these laws contain competing and overlapping regulations and for companies working in multiple states, become an inefficient, expensive burden. For years, the industry has advocated for a national, uniform pharmaceutical traceability system [...]

Continue Reading →

Posted in: Advocacy and Gov Affairs, How distributors make a difference, Policy Outlook & Analysis, Special Features

Leave a Comment (0) →